In the first phase of clinical trials, there is isotopically labeled Nb 131I-GMIB-anti-HER2 VHH1 targeting the HER2 receptor, which is overexpressed in breast carcinoma [73], and M6495, which is used against osteoarthritis, hitting disintegrin and metalloproteinase with thrombospondin motif-5 [74]. Here, ERBB2 is linked to breast carcinoma.